Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. by Courtney A. Swain (15170264)

Networks favouring more connected individuals results in a significant decrease to the likelihood of network recovery. by Adam Lee Miles (14123916)

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. by María Gallardo-Campos (22170919)

Mean KAP scores and standard deviation at different assessment times. by Chikondi Maluwa (20660522)

Subjects:

Achieving Improved Ion Swarm Shaping Based on Ion Leakage Control in Ion Mobility Spectrometry by Jiyao Wang (2121157)

“…The preserved linearity means avoiding excessive ion loss and shape distortion, ultimately leading to optimal resolving power. …”

No significant diurnal rhythmicity of short chain fatty acids in the blood was observed. by Weiran Shan (16969688)

The mean and standard deviation of outcome measures. by Soheila Qanbari (20455173)

Subjects:

Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i> by Razia Rashid Rahil (22772495)

“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P_i-induced VSMCs. …”

RcbA and RcbB co-operatively decrease motility independent of CaCl₂ concentration. by Shobnom Mustaree (21728815)

Deep crypt secretory (DCS) cells are predominantly distributed in the proximal colon, with a progressive decrease towards the distal colon. by Daisuke Sugahara (2047696)

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: